Table 1.
Study period | |||||
---|---|---|---|---|---|
Enrollment/allocation | Post-allocation | Follow-up | Close-out | ||
Timepoint | D0 (= BL) | D0 (= BL) | W1, W2, W3 | W4 | W12 |
Enrollment | |||||
Clinical evaluation | X | ||||
Eligibility screen | X | ||||
Allocation | X | ||||
Interventions | |||||
rESWT | X | X | |||
C + E | X | X | |||
Assessments | |||||
A, G, BH, BW, Du, ES, MS, Co | X | ||||
Safety | X | X | X | X | |
PSEQ score | X | X | X | X | |
NRS score | X | X | X | X | |
OLBPDQ score | X | X | X | X | |
PHQ-9 score | X | X | X | X |
D0, day zero; BL, baseline; W, week; rESWT, radial extracorporeal shock wave therapy; C + E, celecoxib and eperisone; A, age; G, gender; BH, body height; BW, body weight; Du, duration, ES, education status; MS, marriage status; Co, comorbidities; PSEQ, Pain Self-Efficacy Questionnaire; NRS, numerical rating scale; OLDPDQ, Oswestry Low Back Pain Disability Questionnaire; PHQ-9, Patient Health Questionnaire 9